BioSpace News Archive

ANI Pharmaceuticals, Inc. announced financial results and business highlights for the three months ended March 31, 2024.

SN Bioscience Co. Ltd. announced on May 7 that the FDA has granted Fast Track Designation for small cell lung cancer for SNB-101, a new drug for polymer nanoparticle anticancer under clinical trial.

Novavax, Inc., a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, has entered into a co-exclusive licensing agreement with Sanofi.

Editas Medicine, Inc., a clinical-stage gene editing company, announced the presentation of preclinical data demonstrating several in vivo capabilities towards developing transformative in vivo gene editing medicines.

Affinia Therapeutics announced the presentation of new preclinical data on its novel AAV capsids for genetic cardiomyopathies and diseases of the central nervous system such as amyotrophic lateral sclerosis, as well as the Company’s high-yield manufacturing process.

Capsida Biotherapeutics announced new preclinical data that demonstrate the potential of its next-generation intravenously administered gene therapy candidate, CAP-003, to safely and effectively treat Parkinson’s disease associated with GBA mutations.

Centogene N.V., the essential life science partner for data-driven answers in rare and neurodegenerative diseases, revealed significant growth in the CENTOGENE Biodatabank, the world’s largest real-world data repository for rare and neurodegenerative diseases.

Protalix BioTherapeutics, Inc., a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell-based protein expression system, reported financial results for the quarter ended March 31, 2024, and provided a business and clinical update.

Century Therapeutics, an innovative biotechnology company developing induced pluripotent stem cell -derived cell therapies in immuno-oncology and autoimmune and inflammatory disease, announced two poster presentations at the ASGCT 27th Annual Meeting.

Moderna, Inc. announced it has been notified by the U.S. Food and Drug Administration that due to administrative constraints, the agency does not expect to complete its review of the Biologics License Application for mRNA-1345, Moderna’s investigational respiratory syncytial virus vaccine, by the previously communicated Prescription Drug User Fee Act date of May 12, 2024.